Mixed Oligoastrocytoma (MOA)

From WikiCNS
(Difference between revisions)
Jump to: navigation, search
 
Line 1: Line 1:
Definition: MOA is a tumor composed of a conspicuous mixture of two distinct cell types morphologically resembling the tumor cells in oligodendroglioma and LGG. MOA is a WHO Grade II glioma.
+
{{appr}}
 +
{{TOCRight}}
  
Epidemiology: Because of the variability in criteria used to distinguish MAO from oligodendroglioma or LGG, it is difficult to estimate its incidence. Males appear to be slightly more affected (1.2:1).
+
==Definition==
 +
MOA is a tumor composed of a conspicuous mixture of two distinct cell types morphologically resembling the tumor cells in oligodendroglioma and LGG. MOA is a WHO Grade II glioma.
  
Localization: Like oligodendrogliomas, MOA typically occurs in the cortex and white matter of the cerebral hemispheres, most commonly in the frontal lobe.
+
==Epidemiology==
 +
Because of the variability in criteria used to distinguish MAO from oligodendroglioma or LGG, it is difficult to estimate its incidence. Males appear to be slightly more affected (1.2:1).
  
Clinical presentation: Patients with MOA present in a manner similar to patients with oligodendrogliomas or LGG.
+
==Localization==
 +
Like oligodendrogliomas, MOA typically occurs in the cortex and white matter of the cerebral hemispheres, most commonly in the frontal lobe.
  
Imaging: MOA presents with radiographic features indistinguishable from those of an oligodendroglioma.
+
==Clinical presentation==
 +
Patients with MOA present in a manner similar to patients with oligodendrogliomas or LGG.
  
Macroscopy: MOA is macroscopically indistinguishable from an oligodendroglioma, though its cellular heterogeneity may manifest as variations in tumor density and color.
+
==Imaging==
 +
MOA presents with radiographic features indistinguishable from those of an oligodendroglioma.
  
Histopathology: The diagnosis of MOA requires the presence of both an oligodendroglial and astrocytic neoplastic component. These components may be biphasic or intermingled. Overally, MOAs have mildly to moderately increased cellularity, with no or low mitotic activity.
+
==Macroscopy==
 +
MOA is macroscopically indistinguishable from an oligodendroglioma, though its cellular heterogeneity may manifest as variations in tumor density and color.
  
Molecular genetics: MOAs often display a biphasic pattern of genetic mutations common to oligodendrogliomas and LGGs.
+
==Histopathology==
 +
The diagnosis of MOA requires the presence of both an oligodendroglial and astrocytic neoplastic component. These components may be biphasic or intermingled. Overally, MOAs have mildly to moderately increased cellularity, with no or low mitotic activity.
  
Prognosis: Mean survival time following medical and surgical intervention is 6.3 years, with 5- and 10-year survival rates of 58% and 32%, respectively. Risk of malignant progression is thought to correspond to the astrocytic component of the tumor. Factors though to confer more favorable outcome include young age, chromosomes 1p and 19q deletion, frontal location, gross total surgical resection, and post-operative Karnofsky score.
+
==Molecular genetics==
 +
MOAs often display a biphasic pattern of genetic mutations common to oligodendrogliomas and LGGs.
 +
 
 +
==Prognosis==
 +
Mean survival time following medical and surgical intervention is 6.3 years, with 5- and 10-year survival rates of 58% and 32%, respectively. Risk of malignant progression is thought to correspond to the astrocytic component of the tumor. Factors though to confer more favorable outcome include young age, chromosomes 1p and 19q deletion, frontal location, gross total surgical resection, and post-operative Karnofsky score.
  
 
[[Category: Neurosurgery]]
 
[[Category: Neurosurgery]]

Latest revision as of 18:31, 10 July 2008

Checkmark.gif This article has been reviewed by the NeuroWiki Editorial Board


Contents

[edit] Definition

MOA is a tumor composed of a conspicuous mixture of two distinct cell types morphologically resembling the tumor cells in oligodendroglioma and LGG. MOA is a WHO Grade II glioma.

[edit] Epidemiology

Because of the variability in criteria used to distinguish MAO from oligodendroglioma or LGG, it is difficult to estimate its incidence. Males appear to be slightly more affected (1.2:1).

[edit] Localization

Like oligodendrogliomas, MOA typically occurs in the cortex and white matter of the cerebral hemispheres, most commonly in the frontal lobe.

[edit] Clinical presentation

Patients with MOA present in a manner similar to patients with oligodendrogliomas or LGG.

[edit] Imaging

MOA presents with radiographic features indistinguishable from those of an oligodendroglioma.

[edit] Macroscopy

MOA is macroscopically indistinguishable from an oligodendroglioma, though its cellular heterogeneity may manifest as variations in tumor density and color.

[edit] Histopathology

The diagnosis of MOA requires the presence of both an oligodendroglial and astrocytic neoplastic component. These components may be biphasic or intermingled. Overally, MOAs have mildly to moderately increased cellularity, with no or low mitotic activity.

[edit] Molecular genetics

MOAs often display a biphasic pattern of genetic mutations common to oligodendrogliomas and LGGs.

[edit] Prognosis

Mean survival time following medical and surgical intervention is 6.3 years, with 5- and 10-year survival rates of 58% and 32%, respectively. Risk of malignant progression is thought to correspond to the astrocytic component of the tumor. Factors though to confer more favorable outcome include young age, chromosomes 1p and 19q deletion, frontal location, gross total surgical resection, and post-operative Karnofsky score.

Personal tools